{"id":3600,"date":"2026-11-22T09:34:31","date_gmt":"2026-11-22T09:34:31","guid":{"rendered":"https:\/\/newsraise.com\/in\/2026\/11\/22\/regeneron-drug-antibody-combo-eradicates-tumors-mice\/"},"modified":"2026-11-22T09:34:31","modified_gmt":"2026-11-22T09:34:31","slug":"regeneron-drug-antibody-combo-eradicates-tumors-mice","status":"publish","type":"post","link":"https:\/\/newsraise.com\/in\/2026\/11\/22\/regeneron-drug-antibody-combo-eradicates-tumors-mice\/","title":{"rendered":"Regeneron study shows drug\u2011antibody combo eradicates tumors in mice"},"content":{"rendered":"\n<!-- Quick Adsense WordPress Plugin: http:\/\/quickadsense.com\/ -->\n<div class=\"9fece8afa224fd09e54b043d0febfb58\" data-index=\"1\" style=\"float: none; margin:10px 0 10px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- NR ATF -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-8898941184964366\"\r\n     data-ad-slot=\"4839033563\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p>A team of scientists at Regeneron Pharmaceuticals has reported that a two\u2011part treatment\u2014combining the antibody\u2011drug conjugate Enhertu with an experimental bispecific antibody\u2014completely eliminated tumors in laboratory mice and induced an immune response capable of rejecting re\u2011introduced cancer cells. The findings, published in <i>Nature Communications<\/i>, detail experiments conducted in genetically engineered mouse models of breast and colorectal cancer that express the human CD28 protein on T cells.<\/p>\n<h2>Study design and therapeutic agents<\/h2>\n<p>The investigators used mice whose tumor cells were modified to display the molecular targets required for the therapy. Enhertu, also known as trastuzumab deruxtecan, is an approved drug that couples an anti\u2011HER2 antibody with a cytotoxic payload. It delivers the cell\u2011killing compound directly to HER2\u2011expressing cancer cells and is already used in certain breast, stomach and other HER2\u2011positive tumors.<\/p>\n<p>The experimental component of the regimen is a bispecific antibody engineered to bind two distinct proteins simultaneously: one on the surface of the tumor cell and CD28 on T cells. By engaging CD28, the antibody is intended to provide a co\u2011stimulatory signal that amplifies T\u2011cell activation against the cancer.<\/p>\n<h2>Efficacy in breast cancer models<\/h2>\n<p>In the first set of experiments, mice bearing a HER2\u2011positive breast cancer were treated with Enhertu alone, at doses ranging up to the highest level tested in the study. Even at that maximum dose, fewer than half of the animals achieved a complete tumor response. When the same mice received the bispecific antibody in addition to Enhertu, all nine animals in the combination group experienced full tumor eradication, a result the authors describe as a complete response across the cohort.<\/p>\n<p>To evaluate the durability of the response, the researchers waited at least four weeks after the tumors disappeared and then re\u2011introduced the identical breast cancer cells into the cured mice without providing any further therapy. The previously treated animals rejected the new cancer cells, indicating that the combination had generated a memory immune response capable of recognizing and eliminating the same tumor upon re\u2011exposure.<\/p>\n<p>Interestingly, during the same observation period, a separate colorectal tumor emerged in the same mice. Although those colorectal cancer cells also expressed HER2, the animals did not reject them automatically, suggesting that the immune memory was directed not only at HER2 but also at additional tumor\u2011specific features present in the original breast cancer.<\/p>\n<h2>Immune mechanisms and broader implications<\/h2>\n<p>The study identified CD8\u207a T cells as essential mediators of the therapeutic effect. When the researchers depleted CD8\u207a T cells in the mice, the combination treatment lost its efficacy entirely, underscoring the pivotal role of these cytotoxic lymphocytes. Flow\u2011cytometric analysis of tumor\u2011infiltrating lymphocytes revealed an increased proportion of activated T cells and a broader repertoire of T\u2011cell receptors, a finding that could explain the ability of the immune system to recognize multiple tumor antigens beyond HER2.<\/p>\n<p>Beyond the primary breast cancer model, the authors explored additional antibody\u2011drug pairings. An antibody that targets epidermal growth factor receptor (EGFR) was combined with Enhertu in a breast cancer model that was relatively resistant to Enhertu alone. This regimen achieved tumor rejection in approximately 75\u202f% of the mice, demonstrating that the bispecific approach can enhance the activity of Enhertu against harder\u2011to\u2011treat cancers. The EGFR\u2011targeting antibody is already undergoing early\u2011phase clinical evaluation (phase\u202f1\/2).<\/p>\n<p>In a separate colorectal cancer experiment, the EGFR\u2011targeting bispecific antibody was paired with the chemotherapy agent 5\u2011fluorouracil. While each agent alone had minimal impact on tumor growth, the combination slowed tumor progression markedly. The anti\u2011tumor activity in this setting required both CD8\u207a T cells and natural killer (NK) cells; removal of either cell type reduced the therapeutic benefit, and loss of both cell populations abolished it.<\/p>\n<h2>Limitations and next steps<\/h2>\n<p>The authors caution that mouse models do not capture the full spectrum of potential side effects in humans, and they emphasize that the safety and efficacy of the combination must be validated in clinical trials. Regeneron funded the entire research program, and all authors are current or former Regeneron employees who have filed patent applications related to the bispecific antibody technology.<\/p>\n<p>If the promising preclinical results translate to patients, the strategy could expand the therapeutic reach of existing antibody\u2011drug conjugates like Enhertu, turning them into platforms that actively recruit the patient\u2019s own immune system to sustain tumor control after the drug is cleared.<\/p>\n<p>The study adds to a growing body of evidence that bispecific antibodies, when paired with targeted cytotoxic agents, can convert a primarily cell\u2011killing approach into a durable immunological attack. Future clinical investigations will need to address dosing, potential immune\u2011related toxicities, and the identification of biomarkers that predict which patients are most likely to benefit from such combination regimens.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>A Regeneron preclinical study found that pairing the HER2\u2011targeted drug Enhertu with a bispecific antibody cleared tumors in mice and provoked lasting immune protection.<\/p>\n","protected":false},"author":4,"featured_media":3601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[299],"tags":[4099,4096,4098,3114,4097],"class_list":["post-3600","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-bispecific-antibody","tag-cancer-therapy","tag-enhertu","tag-immunotherapy","tag-regeneron","entry"],"_links":{"self":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts\/3600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/comments?post=3600"}],"version-history":[{"count":0,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/posts\/3600\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/media\/3601"}],"wp:attachment":[{"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/media?parent=3600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/categories?post=3600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsraise.com\/in\/wp-json\/wp\/v2\/tags?post=3600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}